New Low-Dose cocktail aims to outsmart MDS resistance

NCT ID NCT04187703

Recruiting now Disease control Sponsor: Benjamin Tomlinson Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early study tests a new way of giving two FDA-approved drugs (5-azacitidine and decitabine) for myelodysplastic syndromes (MDS), a type of bone marrow failure. Instead of standard doses, the drugs are given at low doses on alternating weeks to try to overcome resistance. About 20 adults with MDS or related disorders will take part to see if this approach improves blood cell counts and reduces side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: 5-azacitidine and decitabine (low-dose, alternating schedule)
What this could lead to: If this works, it could offer a gentler, more effective way to control MDS by using lower doses of two approved drugs in rotation.
What could go wrong: This is a very early, small study (20 people) testing a new dosing schedule. It may not work better than standard treatment, and side effects are still unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MDS/MPN CROSSOVER SYNDROMES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

myelodysplastic syndrome Myelodysplastic Syndromes myelodysplastic/myeloproliferative neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MDS/MPN CROSSOVER SYNDROMES MYELODYSPLASTIC SYNDROMES

Contacts and locations

Locations

Cleveland Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center
RECRUITING

Cleveland, Ohio, 44106, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.